RespireRx Pharmaceuticals Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- RespireRx Pharmaceuticals Inc. RespireRx Pharmaceuticals Inc. (RSPI) is a biopharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals targeting neurological, psychiatric and respiratory disorders caused by neuronal signaling disruptions; its lead candidates include dronabinol, a synthetic cannabinoid agonist of CB1 and CB2 receptors repurposed under the ResolutionRx platform for obstructive sleep apnea, and compounds under the EndeavourRx neuromodulators platform comprising AMPAkines such as CX1739, CX717 and CX1942 that act as positive allosteric modulators of AMPA-type glutamate receptors for conditions including attention deficit hyperactivity disorder, central sleep apnea, opioid-induced respiratory depression, spinal cord injury and cognitive disorders, as well as GABAkines like KRM-II-81 that modulate GABAA receptors for epilepsy, chronic pain and convulsant disorders. The company, formerly known as Cortex Pharmaceuticals Inc. until its name change in December 2015, was founded in 1987 and maintains headquarters at 126 Valley Road, Suite C, Glen Rock, New Jersey; it conducts operations primarily in the United States through clinical-stage research collaborations with institutions such as University College London for AMPAkines in GRIA disorders and Shirley Ryan AbilityLab for spinal cord injury applications, targeting patient populations with high unmet needs including an estimated 29.4 million Americans affected by obstructive sleep apnea and others suffering from epilepsy, ADHD and neurodegenerative conditions. Recent developments include a nearly $1.5 million NIH grant awarded in 2025 for preclinical toxicology and IND-enabling studies of KRM-II-81 for epilepsy treatment spanning through August 2027, a $1.8 million U.S. Department of Defense award to fund Phase 2A and 2B clinical trials of CX1739 for improving bladder function in spinal cord injury patients commencing by late 2024, the commencement of a Rule 506(c) private placement in November 2025 targeting up to $45 million across its platforms including $15 million for dronabinol Phase 3 trials in sleep apnea and an SEC order revoking securities registration with plans to transition common stock trading, alongside fourteen peer-reviewed publications in 2024 and two more in 2025 advancing its pipeline.
Reviewing Cortex Pharmaceuticals (OTCMKTS:RSPI) & Stoke Therapeutics (NASDAQ:STOK)
RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties
RespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Amended and Restated Patent License Agreement
RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury
RespireRx's key asset moves to next stage of NIH initiative
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine
RespireRx Pharmaceuticals strengthens board, adding new director
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors
RespireRX Pharmaceuticals reports ‘highly encouraging' case study results for KRM-II-81
RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient
RespireRX Pharmaceuticals announces Ponto Ventures' MD Will Clodfelter will help drive business development
RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development
RespireRx Pharmaceuticals subsidiary inks MSA for dronabinol manufacturing
RespireRx Pharmaceuticals Inc.'s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services
RespireRx to transfer cannabinoid research program to Australian subsidiary ResolutionRx
RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company
RespireRx Pharmaceuticals' Australia cannabis subsidiary inks LOI securing $3.1M investment
RespireRx Pharmaceuticals highlights analogs of its anti-seizure treatment in scientific publications
RespireRx Pharmaceuticals appoints Joseph Siegelbaum as independent director on its board